Dolca Thomas - 15 May 2025 Form 4 Insider Report for Allakos Inc. (ALLK)

Reporting relationship: Director
Issuer ticker: ALLK
Reported as of: 15 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 May 2025, 16:06:14 UTC
Prior SEC filing: 29 May 2024
Source filing: View source filing
Reporting owner signature: /s/ H. Baird Radford, III, by power of attorney

Key filing fact

Dolca Thomas filed Form 4 for Allakos Inc. (ALLK) on 15 May 2025.

Key facts

This page summarizes Dolca Thomas's Form 4 filing for Allakos Inc. (ALLK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 May 2025, 16:06.

Change

Previous filing in this sequence was filed on 29 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001768239 Primary reporting owner

Thomas Dolca

Relationship: Director
Address: 149 COMMONWEALTH DR, SUITE 1090, MENLO PARK
Signature: /s/ H. Baird Radford, III, by power of attorney
Signature date: 15 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALLK transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -154,786
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 154,786
Exercise price: $5.55
Footnotes: F1

ALLK transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -41,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,000
Exercise price: $1.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Dolca Thomas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc.